Available online on 15.2.2025 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

Open Access **Review Article**

Advancing Pharmaceutical Manufacturing with Digital Twin Simulations: Benefits and Challenges

Pawan I. Naik*[1], Vasant Y. Chavan[2], Swapnil R. Patil[3], Bhupendra R. Patil[3], Dr. Pankaj M.Chaudhari[4],

[1]Associate Professor,Department of Pharmaceutical Chemistry, SPBS'S Shatabdi Institute of Pharmacy, Bamdod, Shamsherpur, Nandurbar, Tal Dist. Nandurbar, (MH) INDIA – 425412.

[2]Assistant Professor, Department of Pharmacology, SPBS'S Shatabdi Institute of Pharmacy, Bamdod, Shamsherpur, Nandurbar, Tal Dist. Nandurbar, (MH) INDIA – 425412.

[3]AssociateProfessor,Department of Pharmaceutics, SPBS'S Shatabdi Institute of Pharmacy, Bamdod, Shamsherpur, Nandurbar, Tal Dist. Nandurbar, (MH) INDIA – 425412.

[4]Principal, SPBS'S Shatabdi Institute of Pharmacy, Bamdod, Shamsherpur, Nandurbar, Tal Dist. Nandurbar, (MH) INDIA

A B S T R A C T

To make the manufacturing sector more intelligent and flexible. DTs are virtual representations of real-world systems that replicate their dynamics and behavior. Physical and virtual components, as well as information exchanges between them, make up a fully-fledged DT. Integrated DTs are used in many different product and process industries. There hasn't been a complete implementation of DT in pharmaceutical manufacturing, despite the pharmaceutical industry's recent adoption of Quality-by-Design (QbD) programs and its current digital transformation to embrace Industry 4.0.

Examining the pharmaceutical industry's success in applying DT solutions is therefore crucial. Giving a summary of the state of DT development and its use in the production of pharmaceuticals and biopharmaceuticals is the goal of this narrative literature review. The latest advancements in Process Analytical Technology (PAT), data integration research, and process modeling techniques are examined. There is also discussion of the difficulties and prospects for further study in this area.

Keywords: Digital twins, Pharmaceutical Manufacturing, Application of Digital Twins, Challenges and Consideration, Future Treads

A R T I C L E I N F O: Received 10 Nov.2024; Review Complete 18 Dec. 2024; Accepted 05 Jan. 2025. ; Available online15 Feb. 2025

Cite this article as:

Naik PL, Chavan VY, Patil SR, Patil BR, Chaudhari PM, Advancing Pharmaceutical Manufacturing with Digital Twin Simulations: Benefits and Challenges , Asian Journal of Pharmaceutical Research and Development. 2025; 13(1):147-151,

DOI: http://dx.doi.org/10.22270/ajprd.v13i1.1518

*Address for Correspondence:

Pawan I. Naik, Associate Professor, Department of Pharmaceutical Chemistry, SPBS'S Shatabdi Institute of Pharmacy, Bamdod, Shamsherpur, Nandurbar, Tal Dist. Nandurbar, (MH) INDIA – 425412

INTRODUCTION

In order to foster innovation, boost efficiency, and boost profitability, modern competitive marketplaces require the adoption of new digital technologies [1]. A surge in the use of digital technologies in manufacturing sectors has resulted from the increased interest in these technologies and their promotion in various facets of economic activity [2]. The development of digital technologies over time has brought about a variety of changes in the manufacturing sector, such as the substitution of computers for paper processing, the development and promotion of the Internet, and the growth of digital communication[3].The current trend toward a fully digitalized manufacturing cycle [4], as well as the use of information technology (IT) and programmable logical controllers (PLC) for automated production [3]. A wide range of applications, including post-manufacturing product tracing and tracking, shop floor control and management, and upstream supply chain management, have been made possible by the waves of digitalization.Governments, agencies, academic institutions, and industries have taken notice of the new digital innovations, including the development of artificial intelligence (AI) [5], Internet of Things (IoT) devices [3,5], and digital twins (DTs) [6]. The community of practice has proposed the concept of Industry 4.0 in order to increase automation and boost productivity and operational efficiency. Industry 4.0's smart technologies, including cloud computing (CC), cyber-physical systems (CPS), big data analytics (BDA), and the growth of the Internet of Things (IoT), are crucial in promoting the shift from conventional to smart production [7,8,9,10].

However, according to the recent survey conducted by[11], the preparedness of the industry for this digitalization move is still unsatisfactory. It is noted that most pharmaceutical and biopharmaceutical processes currently rely on quality control checks, laboratory testing, in-process control checks, and standard batch records to assure product quality, whereas the process data and models are of lower impact. Within pharmaceutical companies, there are gaps in knowledge and familiarization with the new digitalization move, resulting in a roadblock in strategic and shop floor implementation of such technologies.[12]

BENEFITS OF DIGITAL TWINS IN PHARMACEUTICAL MANUFACTURING

Enhanced Process Monitoring and Optimization

- Real-time Insights: Digital twins allow for continuous monitoring of manufacturing processes by collecting real-time data from sensors embedded in the equipment. These data points provide a live representation of the system’s performance.
- Predictive Maintenance: By simulating different operational scenarios, digital twins can predict equipment failures, allowing for proactive maintenance, reducing downtime, and extending the lifespan of expensive machinery.
- Process Optimization: DTs enable manufacturers to test various process parameters in the virtual world before implementing changes in real-life operations, ensuring the most efficient and cost-effective methods are used.[13]

Improved Product Quality and Consistency

- Process Control: By replicating the entire production process, DTs can simulate different variables affecting product quality. This ensures that any anomalies are detected early, reducing defects and variations in drug quality.
- Data-Driven Quality Assurance: Digital twins provide data that can be used to track the entire life cycle of the product, helping manufacturers meet stringent regulatory requirements while ensuring that products are consistently high quality.[14]

Regulatory Compliance and Documentation

- Automated Documentation: DTs assist in maintaining the necessary documentation for regulatory compliance. They automatically track the data related to every stage of production, making it easier for manufacturers to provide the necessary records during inspections.

.

- Faster Approval Process: With accurate, real-time data, digital twins can speed up the validation and approval processes for new drugs by providing clear evidence of process control and consistency.[15]

Supply Chain Optimization

- Forecasting and Demand Planning: Digital twins can model the entire pharmaceutical supply chain, from raw material procurement to distribution. They provide valuable insights into demand forecasting and inventory management, helping companies reduce waste and improve service levels.
- End-to-End Visibility: With a digital twin of the supply chain, manufacturers gain visibility into potential disruptions or inefficiencies in the supply chain, enabling them to respond quickly and ensure smooth operations.[16]

Simulation of Biopharmaceutical Production

- Cell Culture and Bioreactor Modeling: In biopharmaceuticals, digital twins are used to simulate complex biological processes like cell cultures and bioreactor performance. These simulations can guide process development, optimize cell growth conditions, and predict the output of biologic products.
- Gene Therapy and Biologics Production: Digital twins in biologics help ensure consistency and scalability in the production of therapies like gene and cell therapies, which require a highly controlled and reproducible environment.[17]

APPLICATIONS OF DIGITAL TWINS IN PHARMACEUTICAL MANUFACTURING [18]

Drug Development and Manufacturing Simulation

By simulating drug formulations and manufacturing processes, digital twins help design efficient and scalable production methods. This application also reduces time-to-market and enhances the likelihood of successful product development.

Bioprocess Monitoring and Optimization

Digital twins are used to simulate the complex biochemical processes in bioreactors. By creating a model of the bioprocess, manufacturers can optimize key parameters (e.g., pH, temperature, oxygen concentration) and predict the impact of changes to the system.

Facility Layout and Design

DTs can be used for virtual design and layout of manufacturing plants, ensuring that the factory layout is optimal for the production flow. This is particularly useful when scaling production or implementing new production lines, helping to avoid costly redesigns.

Personalized Medicine

Digital twins can also support the development and manufacturing of personalized medicines, where drug doses are tailored to individual patients based on their unique genetic makeup. By simulating patient-specific biological models, manufacturers can optimize drug formulations for specific groups.



Figure1: Application of Digital Twin

CHALLENGES AND CONSIDERATIONS

1. **Data Security and Privacy**: As digital twins rely on large amounts of sensitive data, ensuring the protection of intellectual property and patient privacy is crucial.
2. **High Initial Investment**: Implementing digital twins requires significant upfront costs, including the integration of advanced sensors, software, and computing infrastructure.
3. **Complexity in Integration**: Integrating digital twin technology into existing manufacturing systems can be complex, especially for legacy systems. Customization and compatibility with existing IT infrastructure need to be considered.
4. **Regulatory Concerns**: The use of digital twins must comply with the regulatory frameworks established by bodies like the FDA, EMA, and other international regulatory authorities. Manufacturers need to ensure that digital twins meet the standards for data integrity and traceability.[19]

FUTURE TRENDS AND DEVELOPEMENTS

1. **Artificial Intelligence and Machine Learning Integration**: The incorporation of AI and machine learning with digital twins will enhance predictive capabilities, enabling the system to not only mirror real-time data but also make decisions and optimize processes automatically.
2. **Edge Computing**: Edge computing, combined with digital twins, could allow real-time data processing at the source (e.g., sensors in manufacturing equipment), which would enable faster decision-making and reduce the load on central servers.
3. **Blockchain for Traceability**: Blockchain technology may be integrated with digital twins for secure, tamper-proof documentation of pharmaceutical manufacturing processes, ensuring that data integrity is maintained.
4. **Cloud-Based Digital Twins**: Moving digital twin systems to the cloud will enable greater scalability, flexibility, and collaboration across teams, particularly in global pharmaceutical companies with diverse production sites.[20]

CONCLUSIONS:

Digital Twins in Pharmaceutical and Biopharmaceutical Manufacturing

The integration of Digital Twins (DTs) in pharmaceutical and biopharmaceutical manufacturing represents a paradigm shift, bringing substantial advancements in efficiency, product quality, and regulatory compliance. By creating virtual replicas of physical systems, digital twins enable manufacturers to simulate, monitor, and optimize production processes in real-time, leading to numerous benefits across the entire manufacturing lifecycle.[21]

1. **Enhanced Process Efficiency and Optimization**: DTs provide a virtual representation of manufacturing systems, enabling continuous monitoring and predictive maintenance. This allows for the identification of inefficiencies and the optimization of processes without the need for costly, disruptive physical interventions. These insights also facilitate improved resource allocation and better overall productivity.[22]
2. **Improved Product Quality and Consistency**: The ability to simulate different process scenarios in a virtual environment allows manufacturers to proactively address issues that may affect product quality. Digital twins support stringent quality control by ensuring consistent outcomes and meeting regulatory standards, reducing deviations in drug formulations or production processes.[23]
3. **Regulatory Compliance and Transparency**: With digital twins, pharmaceutical companies can automate data collection and track manufacturing activities, enhancing compliance with regulatory requirements. This

leads to more efficient inspections and approvals, reducing the time to market for new drugs.[24]

4. **Cost Reduction and Risk Mitigation**: The predictive capabilities of DTs help in forecasting potential failures and optimizing maintenance schedules, minimizing downtime and reducing operational costs. The ability to anticipate risks and take corrective action in a virtual environment reduces costly errors and disruptions in the physical manufacturing process.[25]

5. **Support for Biopharmaceutical Innovation**: Digital twins play a crucial role in the production of biologics and cell-based therapies. By simulating complex biological processes, such as cell growth and bioreactor conditions, DTs allow for better control and consistency, accelerating the development and scaling of biopharmaceuticals.[26]

6. **Challenges and Considerations**: Despite the numerous advantages, the implementation of digital twins comes with challenges, such as high initial investments, integration with existing systems, data security concerns, and ensuring regulatory compliance. The technology's complexity and the need for advanced infrastructure can be barriers for some manufacturers, especially those with legacy systems.[27]

7. **Future Potential**: Looking forward, digital twin technology is expected to evolve with the incorporation of AI, machine learning, and blockchain, making them even more powerful tools for the pharmaceutical industry. The cloud and edge computing will enable greater scalability, collaboration, and faster decision-making. These advancements will make digital twins a key driver of digital transformation within the pharmaceutical and biopharmaceutical sectors.[28]

In conclusion, Digital Twins offer significant value to the pharmaceutical and biopharmaceutical manufacturing industries by enabling smarter, more efficient production, ensuring product quality, and facilitating compliance with regulatory frameworks. While there are hurdles to overcome in terms of cost, integration, and security, the long-term benefits, including cost savings, improved quality, and enhanced innovation, make digital twins a crucial investment for the future of manufacturing in the life sciences sector.[29]

REFERENCES

1. Legner, C.; Eymann, T.; Hess, T.; Matt, C.; Böhmann, T.; Drews, P.; Mädche, A.; Urbach, N.; Ahlemann, F. Digitalization: Opportunity and Challenge for the Business and Information Systems Engineering Community. *Bus. Inf. Syst. Eng.* **2017**, *59*, 301–308.
2. Kritzinger, W.; Karner, M.; Traar, G.; Henjes, J.; Sihn, W. Digital Twin in manufacturing: A categorical literature review and classification. *IFAC-PapersOnLine* **2018**, *51*, 1016–1022.
3. Oztemel, E.; Gursev, S. Literature review of Industry 4.0 and related technologies. *J. Intell. Manuf.* **2018**, *31*, 127–182.
4. Tao, F.; Cheng, J.; Qi, Q.; Zhang, M.; Zhang, H.; Sui, F. Digital twin-driven product design, manufacturing and service with big data. *Int. J. Adv. Manuf. Technol.* **2018**, *94*, 3563–3576.
5. Venkatasubramanian, V. The promise of artificial intelligence in chemical engineering: Is it here, finally? *AIChE J.* **2019**, *65*, 466–478.
6. Bao, J.; Guo, D.; Li, J.; Zhang, J. The modelling and operations for the digital twin in the context of manufacturing. *Enterp. Inf. Syst.* **2018**, *13*, 534–556.
7. Tao, F.; Qi, Q.; Wang, L.; Nee, A.Y.C. Digital Twins and Cyber–Physical Systems toward Smart Manufacturing and Industry 4.0: Correlation and Comparison. *Engineering* **2019**, *5*, 653–661.
8. Haag, S.; Anderl, R. Digital twin—Proof of concept. *Manuf. Lett.* **2018**, *15*, 64–66.
9. Litster, J.; Bogle, I.D.L. Smart Process. Manufacturing for Formulated Products. *Engineering* **2019**, *5*, 1003–1009.
10. Tourlomousis, F.; Chang, R.C. Dimensional Metrology of Cell-matrix Interactions in 3D Microscale Fibrous Substrates. *Procedia CIRP* **2017**, *65*, 32–37.
11. Khan, M.; Wu, X.; Xu, X.; Dou, W. Big data challenges and opportunities in the hype of Industry 4.0. In Proceedings of the 2017 IEEE International Conference on Communications (ICC), Paris, France, 21–25 May 2017.
12. Li, X.; Li, D.; Wan, J.; Vasilakos, A.V.; Lai, C.-F.; Wang, S. A review of industrial wireless networks in the context of Industry 4.0. *Wirel. Netw.* **2015**, *23*, 23–41.
13. Uhlemann, T.H.J.; Schock, C.; Lehmann, C.; Freiberger, S.; Steinhilper, R. The Digital Twin: Demonstrating the Potential of Real Time Data Acquisition in Production Systems. *Procedia Manuf.* **2017**, *9*, 113–120.
14. Belanger, J.; Venne, P.; Paquin, J.-N. The What, Where and Why of Real-Time Simulation. *Planet RT.* **2010**, *1*, 37–49.
15. Roman-Ospino, A.D.; Singh, R.; Ierapetritou, M.; Ramachandran, R.; Mendez, R.; Ortega-Zuniga, C.; Muzzio, F.J.; Romanach, R.J. Near infrared spectroscopic calibration models for real time monitoring of powder density. *Int. J. Pharm.* **2016**, *512*, 61–74.
16. Damiani, L.; Demartini, M.; Guizzi, G.; Revetria, R.; Tonelli, F. Augmented and virtual reality applications in industrial systems: A qualitative review towards the industry 4.0 era. *IFAC-PapersOnLine* **2018**, *51*, 624–630.
17. Zühlke, D.; Gorecky, D.; Schmitt, M.; Loskyll, M. Human-machine-interaction in the industry 4.0 era. In Proceedings of the 2014 12th IEEE International Conference on Industrial Informatics (INDIN), Porto Alegre, Brazil, 27–30 July 2014.
18. Zhuang, C.; Liu, J.; Xiong, H. Digital twin-based smart production management and control framework for the complex product assembly shop-floor. *Int. J. Adv. Manuf. Technol.* **2018**, *96*, 1149–1163.
19. Leng, J.; Zhang, H.; Yan, D.; Liu, Q.; Chen, X.; Zhang, D. Digital twin-driven manufacturing cyber-physical system for parallel controlling of smart workshop. *J. Ambient Intell. Humaniz. Comput.* **2018**, *10*, 1155–1166.
20. Rosen, R.; von Wichert, G.; Lo, G.; Bettenhausen, K.D. About The Importance of Autonomy and Digital Twins for the Future of Manufacturing. *IFAC-PapersOnLine* **2015**, *48*, 567–572.
21. Mayani, M.G.; Svendsen, M.; Oedegaard, S.I. Drilling Digital Twin Success Stories the Last 10 Years. In Proceedings of the SPE Norway One Day Seminar, Bergen, Norway, 18 April 2018.
22. Schleich, B.; Anwer, N.; Mathieu, L.; Wartzack, S. Shaping the digital twin for design and production engineering. *CIRP Ann.* **2017**, *66*, 141–144.
23. Grieves, M. Digital Twin: Manufacturing Excellence through Virtual Factory Replication. *White Paper* **2014**, *1*, 1–7.
24. Grieves, M.; Vickers, J. Digital Twin: Mitigating Unpredictable, Undesirable Emergent Behavior in Complex Systems. In *Transdisciplinary Perspectives on Complex Systems*; Springer: Cham, Switzerland, 2017; pp. 85–113.
25. Stark, R.; Fresemann, C.; Lindow, K. Development and operation of Digital Twins for technical systems and services. *CIRP Ann.* **2019**, *68*, 129–132.
26. Glaessgen, E.H.; Stargel, D.S. The Digital Twin Paradigm for Future NASA and U.S. Air Force Vehicles. In Proceedings of the 53rd AIAA/ASME/ASCE/AHS/ASC Structures, Structural Dynamics and

Materials Conference—Special Session on the Digital Twin, Honolulu, HI, USA, 23–26 April 2012.

27. O'Connor, T.F.; Yu, L.X.; Lee, S.L. Emerging technology: A key enabler for modernizing pharmaceutical manufacturing and advancing product quality. *Int. J. Pharm.* **2016**, *509*, 492–498.

28. Ding, B. Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains. *Process Saf. Environ. Prot.* **2018**, *119*, 115–130.

29. Barenji, R.V.; Akdag, Y.; Yet, B.; Oner, L. Cyber-physical-based PAT (CPbPAT) framework for Pharma 4.0. *Int. J. Pharm.* **2019**, *567*, 118445.